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Purpose: In osteoarthritis (OA), synovial inﬂammation plays a
critical role, in addition to cartilage catabolism and bone morpho-
logical changes. Previous work from our laboratory has shown that
the 21-amino-acid vasoconstrictor peptide endothelin-1 (ET-1) is
overexpressed in OA tissues. It promotes cartilage catabolism
and subsequent synovial inﬂammation (along with kinins, cy-
tokines, and degradative enzymes), via its speciﬁc A-type receptor
(ETAR), by activating proinﬂammatory signalling pathways. ETAR
and bradykinin receptor 1 (B1R), the inﬂammatory pain receptor,
are both G-protein-coupled receptors (GPCRs); their speciﬁc lig-
ands are present in OA inﬂammatory exudates. Thus, receptor
cross-talk activation may occur, causing joint pain and inﬂam-
mation. The speciﬁc aim of this study was to characterize the
treatment potential of ETAR and B1R peptide antagonists in both
in vitro and in vivo OA models.
Methods: In vitro, human synoviocytes and chondrocytes were
isolated from knee joint tissues of OA patients undergoing total
knee arthroplasty. Cultured with or without peptide antagonists
speciﬁc for ETAR (BQ123) and/or B1R (R954), they were then
exposed to receptor agonists: des-Arg10-kallidin (dKD) for B1R,
and/or ET-1 for ETAR. Mechanistic studies of cellular activation and
inﬂammatory status were carried out by extracting cellular mRNA
(for RT-PCR analyses) and cellular and secreted proteins (for
Western blot analyses). In vivo, OA was induced in the right knee of
8-week-old male Lewis rats by surgical transection of the anterior
cruciate ligament (ACL). Rats were treated by weekly intra-articular
injections of ETAR antagonist, B1R antagonist, both, or saline
vehicle. Animals were sacriﬁced two months post-operatively, and
knee joints were dissected, imaged by X-ray and micro-magnetic
resonance (MR), and processed for histopathology.
Results: ET-1 stimulation of human OA cells induces B1R ex-
pression, as demonstrated by RT-PCR. B1R colocalizes with ET-1
in endothelial cells and synoviocytes; it was induced in the syn-
ovial inﬂammatory microenvironment. dKD and/or ET-1-induced
active-form MMP1 secretion was reduced upon BQ123 (10 nM)
and R954 treatment (10 nM). Double inhibition had a synergistic
effect. In addition, ET-1 signalling transduction occurs via p70 S6
kinase phosphorylation. In vivo, antagonist-treated (0.6 mM) ACL-
transected rats have less subchondral bone remodelling, thicker
articular cartilage and longer cartilage transverse relaxation time
T2 than sham-treated ACL-transected animals, as detected by
X-ray, MR, and histopathology.
Conclusions: In vitro, ETAR and B1R antagonists reduce proin-
ﬂammatory signaling activation and degradative enzyme secretion
in cultured human cells. In vivo, antagonist treatment may retard
or stabilize the development of morphological changes occurring
in OA. Future work will examine joint pain in vivo, along with
longitudinal imaging studies.
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THE EFFECT OF CHONDROITIN SULFATE ON STRUCTURE
MODIFICATION IN PATIENTS WITH KNEE
OSTEOARTHRITIS: A META-ANALYSIS OF 2-YEAR
RANDOMIZED PLACEBO-CONTROLLED TRIALS
M.C. Hochberg, M. Zhan, P. Langenberg
Univ. of Maryland, Baltimore, MD
Purpose: To update a prior meta-analysis of randomized placebo-
controlled trials designed to assess the effect of chondroitin sulfate
on structure modiﬁcation as measured by change in rate of decline
in minimum joint space width in patients with osteoarthritis (OA)
of the knee.
Methods: The prior meta-analysis pooled data from 4 random-
ized placebo-controlled trials of at least 52 weeks duration and
demonstrated a small signiﬁcant effect of chondroitin sulfate on
the reduction in rate of decline in minimum joint space width
(Curr Med Res Opin 2008;24:3029-35). Since this publication, the
ﬁnal results of The Study on Osteoarthritis Progression Preven-
tion (STOPP) and the 2-year results from the structural substudy
of the Glucosamine/Chondroitin Arthritis Intervention Trial (GAIT)
have been published. The primary outcome of the updated meta-
analysis was the change in minimum tibiofemoral joint space width
in millimeters (mm) over 2 years. Whenever possible, we used
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Abstract 530 – Table 1. Characteristics of Individual Trials included in Meta-analysis
1st author, year No. patients Mean (SD) age of No. (%) women Mean (SD) BMI of Minimum JSW at baseline
randomized patients randomized randomized patients randomized in patients randomized
to CS/placebo to CS/placebo to CS/placebo to CS/placebo to CS/placebo
Michel, 2005 150/150 62.5 (9.1)/63.1 (10.7) 76 (51)/78 (52) 27.7 (5.2)/28.1 (5.5) 2.41 (0.14)/2.35 (0.14)
Sawitzke, 2008 123/134 (only 71/70 were assessable) 56.4 (9.2)/56.6 (8.4) 51 (72)/45 (64) NS/NS 3.86 (0.90)/4.07 (0.93)
Kahan, 2009 309/313 62.9 (0.5)/61.8 (0.5) 216 (70)/209 (67) 28.5 (0.4)/29.0 (0.4) 3.73 (0.08)/3.81 (0.07)
data from the intention-to-treat populations for pooling. Results
were summarized for both the absolute difference between the
chondroitin sulfate and placebo-treated groups as well as the
standardized effect size using the pooled standard deviations.
Fixed effects models were used as the I2 statistic showed no evi-
dence of between-trial heterogeneity. All analyses were perfomred
using RevMan version 5 software (www.cc-ims.net).
Results: Results from 3 randomized placebo-controlled trials of 2
years duration were included in this pooled analysis; characteris-
tics of the individual trials are shown in the Table. Overall, data
from 530 patients who were randomized to chondroitin sulfate at
a dose of 800 mg/day and 533 patients who were randomized to
placebo were included in the pooled analysis. The pooled mean
difference in decline in minimum tibiofemoral joint space width over
2 years was 0.13 mm (95% conﬁdence intervals [CI] 0.06, 0.19)
less in the chondroitin sulfate treated groups compared to the
placebo treated groups (P = 0.0002). This difference corresponds
to an effect size of 0.23 (95% CI 0.11, 0.35) (P = 0.0002).
Conclusions: These data demonstrate that chondroitin sulfate at
a dose of 800 mg/day is effective for reducing the rate of decline in
minimum medial tibiofemoral joint space width in patients with knee
OA over 2 years. These results support OARSI recommendations
for the use of chondroitin sulfate as a structure-modifying agent
for patients with knee OA.
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ANTI-INFLAMMATORY EFFECTS AND GASTROINTESTINAL
SAFETY OF THE CYCLOOXYGENASE-INHIBITING NITRIC
OXIDE DONATOR (CINOD) HCT 1026
S. Viappiani1, P. Pﬁster1, J. Raud2, M. Bolla1
1NicOx R&D, Sophia-Antipolis, France; 2AstraZeneca, Sodertalje,
Sweden
Purpose: Long-term use of non steroidal anti-inﬂammatory drugs
(NSAIDs) for the treatment of inﬂammatory conditions such as
osteoarthritis is hampered by gastrointestinal (GI) side effects
and increased potential for cardiovascular events. HCT 1026 is a
cyclooxygenase-inhibiting nitric oxide donator (CINOD) providing
balanced cyclooxygenases inhibition along with the release of nitric
oxide (NO). Through NO donation, HCT 1026 may offer improved
tolerability over traditional NSAIDs, potentially by mitigating the
detrimental effects caused by prostaglandin suppression. The
aim of this study is to characterize the anti-inﬂammatory activity,
gastrointestinal tolerability and in vivo NO release of HCT 1026, a
ﬂurbiprofen-based CINOD, in animal models
Methods: Pleural inﬂammation was induced in anaesthetised
Sprague-Dawley rats by injection of 1% carrageenan into the
thoracic cavity. Animals were euthanized 4h later and thoracic
exudates collected for determination of volume and leukocyte in-
ﬁltration. HCT 1026, ﬂurbiprofen (both at 12.5 and 50 μmol/kg)
or vehicle were administered by gavage 1h prior to carrageenan
injection. GI tolerability was assessed in rats treated twice daily
with vehicle or 40 μmol/kg HCT 1026 or ﬂurbiprofen and sacriﬁced
after 5-7 days for determination of stomach and ileum damage
(presence of ulcers, adhesions and ileum damage score in mm).
In vivo NO donation was tested in New Zealand rabbits previously
anaesthetised, ventilated, and cannulated in the carotid artery for
blood pressure (BP) measurement. Animals were treated with 30
mg/kg L-NAME to quench endogenous NO production and HCT
1026 or ﬂurbiprofen (100 μmol/kg in 6 min, infusion in the jugular
vein) or vehicle (DMSO) were administered following a cross-over
protocol (1 h wash out)
Results: HCT 1026 (12.5 and 50 μmol/kg) dose-dependently in-
hibited carrageenan-induced pleural ﬂuid accumulation (46 and 61
% reduction vs. control, respectively) and neutrophil inﬁltration (22
and 48% reduction vs. control, respectively), similar to equimolar
doses of ﬂurbiprofen.
Administration of 40 μmol/kg HCT 1026 for 7 days was well
tolerated and caused only a slight reduction in haematocrit (8%
decrease vs. vehicle), while administration of an equimolar amount
of ﬂurbiprofen strikingly decreased haematocrit (25% vs. vehicle),
causing death of almost all animals before the end of the study.
Analysis of the GI tract at sacriﬁce revealed no gastric ulcers
in HCT 1026-treated animals, with adhesions in 2 out of 10
animals and minimal ileum damage (0.2±0.1 mm). In contrast,
ﬂurbiprofen caused gastric ulcers in 2 out of 9 animals, adhesions
in all animals, and extensive ileum damage (21.4±3.6 mm).In
rabbits pretreated with L-NAME, infusion of HCT 1026 resulted
in a moderate signiﬁcant increase in exhaled NO (from 0.4±0.15
to 2.3±0.4 ppb) which lasted up to 60 min, and a reduction of
BP of ∼21 cmH2O (15.5 mmHg). Flurbiprofen did not alter these
parameters
Conclusions:HCT 1026 displays effective anti-inﬂammatory prop-
erties comparable to the reference NSAID ﬂurbiprofen in the
pleurisy model, with a superior GI tolerability proﬁle, likely due to
its ability to donate NO (as observed in vivo)
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GASTROINTESTINAL SAFETY OF THE
CYCLOOXYGENASE-INHIBITING NITRIC OXIDE DONATOR
(CINOD) HCT 2037 IN A RAT MODEL OF INFLAMMATION
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1NicOx SA, Sophia-Antipolis, France; 2McMaster Univ., Hamilton,
ON, Canada
Purpose: Chronic treatment of osteoarthritis with non steroidal
anti-inﬂammatory drugs (NSAIDs) is associated with several
gastro-intestinal (GI) side effects. In addition, increased cardio-
vascular risk has been documented following their long-term use.
Cyclooxygenase-inhibiting nitric oxide donators (CINODs) bear
both COX-1 and COX-2-inhibiting activity as well as nitric oxide
(NO) donating properties. The rationale behind this approach is
to increase GI tolerability while retaining the anti-inﬂammatory
properties typical of NSAIDs. Here, we present the GI safety pro-
ﬁle of HCT 2037, a ketoprofen-based CINOD, in a rat model of
inﬂammation.
Methods: Efﬁcacy and gastric damage were evaluated in parallel
in the carrageenan-induced model of inﬂammation. Male Wistar
rats were orally administered 0.3-35.7 mg/kg HCT 2037 or equimo-
lar doses of ketoprofen 30 min before carrageenan injection into
the right paw. Edema was measured at regular times for further
5 h. Rats were then euthanized and the stomachs excised and
analyzed to assess gastric damage score (sum in mm of all hem-
orrhagic erosions). UD30 and ED30 were calculated as the doses
